Ghana vs Mexico: HIV/AIDS deaths averted by antiretroviral therapy
Ghana
12,358 deaths
in 2024
Mexico
12,379 deaths
in 2024
Ghana rank
20th
Mexico rank
19th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Ghana
- Mexico
How they compare
Mexico currently reports 12,379 deaths against 12,358 deaths in Ghana, a difference of 21 deaths.
The two have swapped places 4 times across 35 shared years of data; in 1990 it was Mexico ahead.
Ghana ranks 20th and Mexico ranks 19th of 157 countries.
Across the 4 decades both report, Ghana averaged higher in 1 and Mexico in 3.
Head to head by decade
| Decade | Ghana | Mexico | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 379.05 deaths | 379.05 deaths | Mexico |
| 2000s | 1,525 deaths | 3,660 deaths | 2,135 deaths | Mexico |
| 2010s | 9,063 deaths | 8,109 deaths | 953.53 deaths | Ghana |
| 2020s | 11,466 deaths | 11,646 deaths | 179.7 deaths | Mexico |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Ghana or Mexico?
- Mexico, at 12,379 deaths against 12,358 deaths in Ghana as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Ghana and Mexico?
- 21 deaths, with Mexico ahead.
- How many years of comparable data are there for Ghana and Mexico?
- 35 years are reported by both, from 1990 to 2024.
- How do Ghana and Mexico rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Ghana ranks 20th and Mexico ranks 19th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.